Online inquiry

IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5509MR)

This product GTTS-WQ5509MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL17A&IL17F gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002190.3; NM_052872.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605; 112744
UniProt ID Q16552; Q96PD4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5509MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4846MR IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BT-062
GTTS-WQ9677MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ15791MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ11702MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MILR1444A
GTTS-WQ15048MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SRF-231
GTTS-WQ13654MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ9747MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA JR-141
GTTS-WQ10830MR IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA M7824
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW